Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. The lancet. Gastroenterology & hepatology Eslam, M., Ahmed, A., Després, J. P., Jha, V., Halford, J. C., Wei Chieh, J. T., Harris, D. C., Nangaku, M., Colagiuri, S., Targher, G., Joshi, S., Byrne, C. D., Khunti, K., Nguyen, M. H., Gish, R. G., George, J. 2021

Abstract

With the global epidemics of obesity and associated conditions, including type 2 diabetes, metabolic dysfunction-associated fatty liver disease, chronic kidney disease, hypertension, stroke, cardiovascular disease, osteoporosis, cancer, and cognitive changes, the prevalence of multimorbidity is rapidly increasing worldwide. In this Review, a panel of international experts from across the spectrum of metabolic diseases come together to identify the challenges and provide perspectives on building a framework for a virtual primary care-driven, patient-centred, multidisciplinary model to deliver holistic care for patients with metabolic dysfunction-associated fatty liver disease and associated metabolic diseases. We focus on clinical care and innovative trial design for metabolic dysfunction-associated fatty liver disease and associated metabolic diseases. This work represents a call to action to promote collaboration and partnerships between stakeholders for improving the lives of people with, or at risk of, metabolic dysfunction-associated fatty liver disease and associated metabolic diseases.

View details for DOI 10.1016/S2468-1253(21)00132-1

View details for PubMedID 34265276